,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca,Roche
['gi ']
important safety update of db03 presented by at #asco22. key takeaway messages: with additional follow up, no g4-5 ild events with t-dxd; gi toxicities quite common, important to master their prevention and management. 
MD, Research Fellow @DanaFarber | @harvardmed | @IEOufficiale | @LaStatale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert.